Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide
Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide OEM relationship with Elscint.
MediSurf users employ a standard World Wide Web browser and applets based on the Java programming language developed by Sun Microsystems. The browser is used to access the MediSurf DICOM 3.0-compliant server, which is linked to both clinical image and data sources. There is no need for installation of additional hardware or software at end-user sites, according to the company.
Algotec debuted MediSurf at last year's Radiological Society of North America meeting (SCAN Special Report 12/96). In addition to three beta sites in the U.S., Canada, and Germany, MediSurf has been installed at nine other institutions. Two MediSurf packages have been installed in the U.S.
Initially, Algotec will market MediSurf in the U.S. through OEMs. In a few months, however, the firm will sell MediSurf via regional distributors as well as through direct sales in some cases, said Kobi Margolin, Algotec marketing manager. Because the company expects OEMs to contribute most of MediSurf's sales, Algotec is actively looking for OEM relationships in addition to the Elscint agreement, Margolin said.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.